Application of dexmedetomidine in bronchoalveolar lavage treatment of severe pneumonia

Effect of dexmedetomidine on anesthesia effect and SP-A expression of bronchoalveolar lavage in patients with severe pneumonia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052571

Enrollment

Unknown

Registered

2021-10-31

Start date

2021-11-05

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe pneumonia

Interventions

experimental group:Inject dexmedetomidine

control group:Inject saline

Eligibility

Sex/Gender

All

Age

45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with severe pneumonia, meet the diagnostic criteria for severe pneumonia established by the American Thoracic Society; 2. Gender and age are not limited; 3. All received mechanical ventilation for tracheal intubation; 4. Compliant with fiberoptic bronchoscopy and alveolar lavage treatment Indications.

Exclusion criteria

Exclusion criteria: 1. Severe heart insufficiency, liver and kidney failure; 2. Serious infection of the extrapulmonary system; 3. Severe bleeding tendency, coagulopathy; 4. Other contraindications for bronchoscopy alveolar lavage.

Design outcomes

Primary

Measure	Time frame
Alveolar surfactant protein A;blood gas analysis;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;tumor necrosis factor-a;superoxide dismutase;interleukin- 6;malonaldehyde;	—

Countries

China

Contacts

Public ContactTian Haitao

Jining First People's Hospital

tianhaiqx@126.com+86 15668168906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026